The HGF/c-MET axis as a potential target to overcome survival signals and improve therapeutic efficacy in multiple myeloma

Abstract

Multiple myeloma (MM) accounts for about 10% of hematologic malignancies, and it is the second most frequent hematologic neoplasm after lymphomas. The exact etiology of MM is still unknown and, despite the introduction of more effective and safe drugs in recent years, MM remains an incurable disease. Intrinsic and acquired resistance of malignant B cells to pharmacological treatments still represents an obstacle for survival improvement. Activation of the hepatocyte growth factor/c-MET axis has been reported as involved in MM pathogenesis: hepatocyte growth factor (HGF) levels are in fact higher in sera from MM patients than in healthy controls, the HGF/c-MET pathway may be activated in an autocrine or paracrine manner, and it is interesting to note that a higher c-MET phosphorylation is associated with disease progression. Several studies have further demonstrated the over-activation of c-MET either in resistant cell lines or in primary malignant plasma cells purified from bone marrow of patients resistant to chemotherapy. For this reason, c-MET has been proposed as a potential marker of multidrug resistance in the disease. Here, we first summarize the potential role of HGF/c-MET interaction in disease evolution and then describe novel approaches targeting this axis which could be conceptually utilized, alone or in combination with standard therapies, to treat MM and possibly overcome drug resistance.

Keywords

HGF / c-MET / microenvironment / multiple myeloma / multidrug resistance marker

References

[1] Kawano M,Matsuda T.Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas.Nature1988;332:83-5

[2] Borset M,Naume B.Lack of IL-1 secretion from human myeloma cells highly purified by immunomagnetic separation.Br J Haematol1993;85:446-51

[3] Klein B,Jourdan M.Paracrine rather than autocrine regulation of myeloma-cell growth and differentiation by interleukin-6.Blood1989;73:517-26

[4] Mahindra A,Anderson KC.Multiple myeloma: biology of the disease.Blood Rev2010;24:S5-11

[5] Hofmann JN,Landy R.A prospective study of circulating chemokines and angiogenesis markers and risk of multiple myeloma and its precursor.JNCI Cancer Spectr2020;4:pkz104 PMCID:PMC7083234

[6] Iwasaki T,Ogata A,Kitano M.Clinical significance of vascular endothelial growth factor and hepatocyte growth factor in multiple myeloma.Br J Haematol2002;116:796-802

[7] Seidel C,Turesson I,Sundan A.Elevated serum concentrations of hepatocyte growth factor in patients with multiple myeloma. The Nordic Myeloma Study Group.Blood1998;91:806-12

[8] Turesson I,Ahlgren T.Prognostic evaluation in multiple myeloma: an analysis of the impact of new prognostic factors.Br J Haematol1999;106:1005-12

[9] Börset M,Seidel C,Waage A.Hepatocyte growth factor and its receptor c-met in multiple myeloma.Blood1996;88:3998-4004

[10] Borset M,Espevik T,Waage A.Concomitant expression of hepatocyte growth factor/scatter factor and the receptor c-MET in human myeloma cell lines.J Biol Chem1996;271:24655-61

[11] Børset M,Hjorth-Hansen H,Sundan A.The role of hepatocyte growth factor and its receptor c-Met in multiple myeloma and other blood malignancies.Leuk Lymphoma1999;32:249-56

[12] Mahtouk K,Spaargaren M.The HGF/MET pathway as target for the treatment of multiple myeloma and B-cell lymphomas.Biochim Biophys Acta2010;1806:208-19

[13] Rampa C,Våtsveen TK.Identification of the source of elevated hepatocyte growth factor levels in multiple myeloma patients.Biomark Res2014;2:8 PMCID:PMC4022385

[14] Tjin EP,Kataoka H,Pals ST.Multiple myeloma cells catalyze hepatocyte growth factor (HGF) activation by secreting the serine protease HGF-activator.Blood2004;104:2172-5

[15] Hov H,Rø TB.A selective c-met inhibitor blocks an autocrine hepatocyte growth factor growth loop in ANBL-6 cells and prevents migration and adhesion of myeloma cells.Clin Cancer Res2004;10:6686-94

[16] Rocci A,Aschero S.MET dysregulation is a hallmark of aggressive disease in multiple myeloma patients.Br J Haematol2014;164:841-50

[17] Giannoni P,Quarto R.An interaction between hepatocyte growth factor and its receptor (c-MET) prolongs the survival of chronic lymphocytic leukemic cells through STAT3 phosphorylation: a potential role of mesenchymal cells in the disease.Haematologica2011;96:1015-23 PMCID:PMC3128221

[18] Takai K,Matsumoto K.Hepatocyte growth factor is constitutively produced by human bone marrow stromal cells and indirectly promotes hematopoiesis.Blood1997;89:1560-5

[19] Derksen PW,Meijer HP.The hepatocyte growth factor/Met pathway controls proliferation and apoptosis in multiple myeloma.Leukemia2003;17:764-74

[20] Zaman S,Yang J.Targeting the pro-survival protein MET with tivantinib (ARQ 197) inhibits growth of multiple myeloma cells.Neoplasia2015;17:289-300 PMCID:PMC4372650

[21] Hov H,Holien T.c-Met signaling promotes IL-6-induced myeloma cell proliferation.Eur J Haematol2009;82:277-87 PMCID:PMC2704927

[22] Kristensen IB,Rø TB.Decorin is down-regulated in multiple myeloma and MGUS bone marrow plasma and inhibits HGF-induced myeloma plasma cell viability and migration.Eur J Haematol2013;91:196-200

[23] Huang SY,Yao M.Higher decorin levels in bone marrow plasma are associated with superior treatment response to novel agent-based induction in patients with newly diagnosed myeloma - a retrospective study.PLoS One2015;10:e0137552 PMCID:PMC4574783

[24] Li X,Yaccoby S.Role of decorin in the antimyeloma effects of osteoblasts.Blood2008;112:159-68 PMCID:PMC2435686

[25] Bussolino F,Ziche M.Hepatocyte growth factor is a potent angiogenic factor which stimulates endothelial cell motility and growth.J Cell Biol1992;119:629-41 PMCID:PMC2289675

[26] Vacca A,Roncali L.Bone marrow angiogenesis and progression in multiple myeloma.Br J Haematol1994;87:503-8

[27] Zhang YW,Volpert OV.Hepatocyte growth factor/scatter factor mediates angiogenesis through positive VEGF and negative thrombospondin 1 regulation.Proc Natl Acad Sci U S A2003;100:12718-23 PMCID:PMC240684

[28] Jakob C,Zavrski I.Angiogenesis in multiple myeloma.Eur J Cancer2006;42:1581-90

[29] Ferrucci A,Frassanito MA.A HGF/cMET autocrine loop is operative in multiple myeloma bone marrow endothelial cells and may represent a novel therapeutic target.Clin Cancer Res2014;20:5796-807

[30] Bonanno G,Procoli A.Indoleamine 2,3-dioxygenase 1 (IDO1) activity correlates with immune system abnormalities in multiple myeloma.J Transl Med2012;10:247 PMCID:PMC3543251

[31] Rutella S,Procoli A.Hepatocyte growth factor favors monocyte differentiation into regulatory interleukin (IL)-10++IL-12low/neg accessory cells with dendritic-cell features.Blood2006;108:218-27

[32] Børset M,Waage A.Why do myeloma patients have bone disease?.Blood Rev2020;41:100646

[33] Eda H,David Roodman G.Bone disease in multiple myeloma. In: Roccaro AM, Ghobrial IM, editors. Plasma cell dyscrasias. Cham: Springer International Publishing; 2016. p. 251-70.

[34] Bataille R,Marcelli C.Mechanisms of bone destruction in multiple myeloma: the importance of an unbalanced process in determining the severity of lytic bone disease.J Clin Oncol1989;7:1909-14

[35] Moschetta M,Ferrucci A.Novel targeting of phospho-cMET overcomes drug resistance and induces antitumor activity in multiple myeloma.Clin Cancer Res2013;19:4371-82

[36] Rø TB,Fagerli UM.HGF and IGF-1 synergize with SDF-1α in promoting migration of myeloma cells by cooperative activation of p21-activated kinase.Exp Hematol2013;41:646-55

[37] Grano M,Zambonin G.Hepatocyte growth factor is a coupling factor for osteoclasts and osteoblasts in vitro.Proc Natl Acad Sci U S A1996;93:7644-8 PMCID:PMC38800

[38] Standal T,Fagerli UM.HGF inhibits BMP-induced osteoblastogenesis: possible implications for the bone disease of multiple myeloma.Blood2007;109:3024-30

[39] Strømme O,Stokke BT,Arum CJ.Myeloma-derived extracellular vesicles mediate HGF/c-Met signaling in osteoblast-like cells.Exp Cell Res2019;383:111490

[40] Comoglio PM,Boccaccio C.Known and novel roles of the MET oncogene in cancer: a coherent approach to targeted therapy.Nat Rev Cancer2018;18:341-58

[41] Organ SL.An overview of the c-MET signaling pathway.Ther Adv Med Oncol2011;3:S7-S19 PMCID:PMC3225017

[42] Que W.Knockdown of c-Met inhibits cell proliferation and invasion and increases chemosensitivity to doxorubicin in human multiple myeloma U266 cells in vitro.Mol Med Rep2011;4:343-9

[43] Que W,Chuang M.Knockdown of c-Met enhances sensitivity to bortezomib in human multiple myeloma U266 cells via inhibiting Akt/mTOR activity.APMIS2012;120:195-203

[44] Zhang Y,Zhou W.Targeting c-met receptor tyrosine kinase by the DNA aptamer SL1 as a potential novel therapeutic option for myeloma.J Cell Mol Med2018;22:5978-90 PMCID:PMC6237600

[45] Ueki R.A DNA aptamer to c-Met inhibits cancer cell migration.Chem Commun (Camb)2014;50:13131-4

[46] Lath DL,Evans HR.ARQ-197, a small-molecule inhibitor of c-Met, reduces tumour burden and prevents myeloma-induced bone disease in vivo.PLoS One2018;13:e0199517 PMCID:PMC6010293

[47] Baljevic M,Baladandayuthapani V.Phase II study of the c-MET inhibitor tivantinib (ARQ 197) in patients with relapsed or relapsed/refractory multiple myeloma.Ann Hematol2017;96:977-85 PMCID:PMC5406425

[48] Lendvai N,Tsakos I.Phase IB study of cabozantinib in patients with relapsed and/or refractory multiple myeloma.Blood2016;127:2355-6 PMCID:PMC5003505

[49] Misso G,Lombardi A.miR-125b upregulates miR-34a and sequentially activates stress adaption and cell death mechanisms in multiple myeloma.Mol Ther Nucleic Acids2019;16:391-406 PMCID:PMC6479071

[50] Di Martino MT,Amodio N.Synthetic miR-34a mimics as a novel therapeutic agent for multiple myeloma: in vitro and in vivo evidence.Clin Cancer Res2012;18:6260-70 PMCID:PMC4453928

[51] Li L,Zhang W,Gao Y.Scutellarin circumvents chemoresistance, promotes apoptosis, and represses tumor growth by HDAC/miR-34a-mediated down-modulation of Akt/mTOR and NF-κB-orchestrated signaling pathways in multiple myeloma.Int J Clin Exp Pathol2020;13:212-19 PMCID:PMC7061792

[52] Zhang B,Wei J.miR-137 suppresses the phosphorylation of AKT and improves the dexamethasone sensitivity in multiple myeloma cells via targeting MITF.Curr Cancer Drug Targets2016;16:807-17

[53] Zhao Y,Lin J.MiR-144-3p inhibits cell proliferation and induces apoptosis in multiple myeloma by targeting c-Met.Am J Transl Res2017;9:2437-46 PMCID:PMC5446526

[54] Umezu T,Azuma K.Replenishing exosomes from older bone marrow stromal cells with miR-340 inhibits myeloma-related angiogenesis.Blood Adv2017;1:812-23 PMCID:PMC5727805

[55] Du W,Yamada T.NK4, an antagonist of hepatocyte growth factor (HGF), inhibits growth of multiple myeloma cells: molecular targeting of angiogenic growth factor.Blood2007;109:3042-9

[56] Rao L,Giannico D.Targeting angiogenesis in multiple myeloma by the VEGF and HGF blocking DARPin^® protein MP0250: a preclinical study.Oncotarget2018;9:13366-81 PMCID:PMC5862584

[57] Slørdahl TS,Moen SH.Anti-c-MET Nanobody - a new potential drug in multiple myeloma treatment.Eur J Haematol2013;91:399-410

[58] Wood GE,Hilton DM.The role of MET in chemotherapy resistance.Oncogene2021;40:1927-41 PMCID:PMC7979538